Food and Drug Administration

NCT05716854

Phase 1Completed44 people8 Feb 2023clinicaltrials.gov

NCT04542382

CollaboratorPhase 1Completed11 people9 Sept 2020clinicaltrials.gov

NCT04189484

Phase 1Completed72 people6 Dec 2019clinicaltrials.gov

NCT01720147

CollaboratorPhase 1Completed30 people2 Nov 2012clinicaltrials.gov

NCT01440803

CollaboratorPhase 2Completed41 people27 Sept 2011clinicaltrials.gov

NCT00432744

CollaboratorPhase 3Completed24 people8 Feb 2007clinicaltrials.gov

Xinhui Wang

Disulfiram/Copper as a Dual Senolytic Strategy Targeting Tumor and Immune Cell Senescence in ChordomaU01FD00898030 Sept 2026reporter.nih.gov

Massachusetts General Hospital

Disulfiram/Copper as a Dual Senolytic Strategy Targeting Tumor and Immune Cell Senescence in ChordomaU01FD008980US$1m30 Sept 2026reporter.nih.gov

Zhongde Wang

The Building Resistance Against Viral Entities (BRAVE) Innovation CenterU18FD00846424 Sept 2026reporter.nih.gov

Peter Joseph Halfmann

The Building Resistance Against Viral Entities (BRAVE) Innovation CenterU18FD00846424 Sept 2026reporter.nih.gov

University of Wisconsin-madison

The Building Resistance Against Viral Entities (BRAVE) Innovation CenterU18FD008464US$25k24 Sept 2026reporter.nih.gov

Alma Roy

Upgrading NGS Infrastructure to Support Vet-LIRN Capacity-Building GoalsU18FD00890923 Sept 2026reporter.nih.gov

Louisiana State Univ A&m Col Baton Rouge

Upgrading NGS Infrastructure to Support Vet-LIRN Capacity-Building GoalsU18FD008909US$51.5k23 Sept 2026reporter.nih.gov

Johanna I Hamel

Calcium Channel Blocker in Myotonic Dystrophy Type 1 (CAP DM1)R01FD00851023 Sept 2026reporter.nih.gov

University of Rochester

Calcium Channel Blocker in Myotonic Dystrophy Type 1 (CAP DM1)R01FD008510US$1.3m23 Sept 2026reporter.nih.gov

Zhongde Wang

The Building Resistance Against Viral Entities (BRAVE) Innovation CenterU18FD00846422 Sept 2026reporter.nih.gov

Peter Joseph Halfmann

The Building Resistance Against Viral Entities (BRAVE) Innovation CenterU18FD00846422 Sept 2026reporter.nih.gov

University of Wisconsin-madison

The Building Resistance Against Viral Entities (BRAVE) Innovation CenterU18FD008464US$914.9k22 Sept 2026reporter.nih.gov

Pharmacologic Treatments for Female Menopausal Vasomotor Symptoms: A Systematic Review and Meta-analysis for the American College of Physicians

Annals of internal medicine6 Oct 2026

Oral Wegovy Is Associated with Greater Early Weight Loss Than Foundayo in Propensity Matched Adult GLP-1 Users

Preprints.org30 Sept 2026

Implementing a nicotine cap to make America Healthy Again

Health affairs scholar26 Sept 2026